IP Library Granted Patent US 11,535,833
Granted Patent B2
US 11,535,833 · App. 16/771,279 · Granted Dec 27, 2022

Carboxyesterase biocatalysts

Inventors: Kristin K. Brown (Collegeville, PA); Brent M. Dorr (Collegeville, PA); Douglas E. Fuerst (Collegeville, PA); Katherine Joyce Honicker (Collegeville, PA); Lydia Sanchez Jordan (Collegeville, PA); James Patrick Morrison (Collegeville, PA); Nikolay V. Plotnikov (Collegeville, PA); Markus Schober (Stevenage, GB); Rama Voladri (Redwood City, CA)
Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
C12N9/18C12P17/16C12P17/165C12Y301/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,833
App. No.
16/771,279
Granted
Dec 27, 2022
Kind
B2
Abstract

The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.

Claims (29)

1. A carboxyesterase polypeptide having carboxyesterase activity and comprising an amino acid sequence that is at least 93%, or more identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the residue corresponding to X198 in SEQ ID NO: 4 is a leucine (L) residue.

2. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises a residue difference as compared to the amino acid sequence set forth in SEQ ID NO: 4 in at least one residue position selected from the group consisting of: X27, X30, X35, X37, X57, X75, X103, X185, X207, X208, X271, X286, and X296.

3. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises

an aliphatic residue or an aromatic residue at the residue corresponding to X103.

4. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further includes at least one feature selected from the group consisting of: X27 is P; X30 is I, L, or V; X35 is H; X37 is I, L, T, or V; X57 is M; X75 is R; X103 is F, M, or W; X185 is F, I, or M; X207 is E; X208 is R, L, or H; X271 is D; X286 is M, V, or G; and X296 is V, L, or R.

5. The carboxyesterase polypeptide of claim 1 , wherein the carboxyesterase polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4.

6. A process for preparing an amide, wherein components are combined containing:

(a) an ester substrate of the form R1-COOR2, wherein R1 is chosen from: an sp3 carbon with 0 to 3 alkyl substituents; and an aromatic ring, and R2 is chosen from: a methyl group; an ethyl group; and 1-6 carbon alkyl chains;

(b) an amine substrate;

(c) a carboxyesterase polypeptide comprising an amino acid sequence that is at least 93% identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the residue corresponding to X198 in SEQ ID NO: 4 is a L residue; and

(d) a solvent.

7. The process of claim 6 , wherein the carboxyesterase polypeptide in step (c) is prepared in the presence of a salt.

8. The process of claim 7 , wherein the salt is chosen from: sodium sulfate; potassium sulfate; lithium sulfate; sodium phosphate; and potassium phosphate.

9. The process of claim 6 , wherein the solvent is an organic solvent chosen from: toluene; 2-methyltetrahydrofuran; tetrahydrofuran;

dimethylacetamide; methyl isobutyl ketone (MIBK); dichloromethane; tert-butyl methyl ether;

cyclopentyl methyl ether; methyl cyclohexane; dichloromethane; acetonitrile; methyl ethyl ketone; isopropyl acetate; ethanol; isopropanol; ethyl acetate; heptane; xathane; and 2-methyltetrahydrofuran (2-Me-THF); and water.

10. The process of claim 9 , wherein the organic solvent contains up to 3 molar equivalents of water relative to the ester substrate in an amount of from about 0.5% (vol/vol) to about 3% (vol/vol).

11. The process of claim 6 , wherein the ester substrate is ethyl oxazole 5-carboxylate that has the formula:

the amine substrate is 1-isopropy 1piperazine that has the formula:

and the amide is (4-isopropylpiperazin-1-yl)(oxazol-5y1)methanone that has the formula:

12. The process of claim 6 , wherein the ester substrate is ethyl oxazole-5-carboxylate that has the formula:

the amine substrate is cis-2,6-dimethylmorpholine that has the formula:

and the amide is ((2S,6R)-2,6-dimethylmorpholino)(oxazol-5-yl)methanone that has the formula:

13. The process of claim 6 , wherein the reaction comprises: about 40 g/L ethyl oxazole-5-carboxylate, about 44 g/L 1-isopropylpiperazine, and about 20 g/L of a carboxyesterase polypeptide comprises the amino acid sequence set forth in the SEQ ID NO: 4, wherein the carboxyesterase polypeptide is prepared in the presence of sodium sulfate and run in the presence of from about 10 g/L to about 20 g/L water in MIBK.

14. The carboxyesterase polypeptide of claim 3 , wherein X103 is an aromatic residue.

15. The carboxyesterase polypeptide of claim 14 , wherein X103 is a tryptophan (W) residue.

16. The carboxyesterase polypeptide of claim 1 , wherein the amino acid sequence of the carboxyesterase polypeptide further comprises a non-polar residue, an aliphatic residue, or an aromatic residue at the residue corresponding to X185.

17. The carboxyesterase polypeptide of claim 16 , wherein X185 is an aromatic residue.

18. The carboxyesterase polypeptide of claim 17 , wherein X185 is a phenylalanine (F) residue.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2020
From: BROWN, KRISTIN K.; DORR, BRENT M.; FUERST, DOUGLAS E.; HONICKER, KATHERINE JOYCE; JORDAN, LYDIA SANCHEZ; MORRISON, JAMES PATRICK; PLOTNIKOV, NIKOLAY V.; SCHOBER, MARKUS; VOLADRI, RAMA
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 052889/0965 →
Continuity (2)
Provisional Application 62598181 · Dec 13, 2017
Related Publication 20210115417A1 · Apr 22, 2021